Your browser doesn't support javascript.
loading
Immunogenicity of Cemiplimab: Low Incidence of Antidrug Antibodies and Cut-Point Suitability Across Tumor Types.
Valentine, Jenny L; Dengler, Andrew; Zhao, An; Truong, Tiffany; McAfee, Sean; Hassanein, Mohamed; Irvin, Susan C; Chen, Jihua; Meng, Xiao; Yan, Hong; Torri, Albert; Sumner, Giane; Andisik, Matthew D; Paccaly, Anne; Partridge, Michael A.
Afiliación
  • Valentine JL; Bioanalytical Sciences and Pharmacometrics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Dengler A; Bioanalytical Sciences and Pharmacometrics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Zhao A; Bioanalytical Sciences and Pharmacometrics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Truong T; Bioanalytical Sciences and Pharmacometrics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • McAfee S; Bioanalytical Sciences and Pharmacometrics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Hassanein M; Bioanalytical Sciences and Pharmacometrics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Irvin SC; Bioanalytical Sciences and Pharmacometrics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Chen J; Bioanalytical Sciences and Pharmacometrics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Meng X; Bioanalytical Sciences and Pharmacometrics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Yan H; Bioanalytical Sciences and Pharmacometrics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Torri A; Bioanalytical Sciences and Pharmacometrics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Sumner G; Bioanalytical Sciences and Pharmacometrics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Andisik MD; Bioanalytical Sciences and Pharmacometrics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Paccaly A; Bioanalytical Sciences and Pharmacometrics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Partridge MA; Bioanalytical Sciences and Pharmacometrics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
J Clin Pharmacol ; 64(1): 125-136, 2024 Jan.
Article en En | MEDLINE | ID: mdl-37656820
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Neoplasias Tipo de estudio: Guideline / Incidence_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Clin Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Neoplasias Tipo de estudio: Guideline / Incidence_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Clin Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido